← board
FOXOW
distress 8/10 · high distress / dilution risk$0.01today0% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
+9212%
Overview
- Market Cap
- $22.16M
- Volume
- 5.50K
- 52 Week Range
- $0.01 – $0.01
- Total Shares
- 4.26B
- RVOL
- 1.00x
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- 2026-05-27partnershipExclusive worldwide license grant to LongevityFP Technologies for FOXO's epigenetics IP, with royalty and acquisition option.SEC 8-K
- 2026-01-20partnershipPartnership with CompuMed for professional interpretation of on-site echocardiography studies.SEC 8-K
- 2026-01-20partnershipInpatient tele-specialty coverage partnership with Rural Physicians Group for cardiology, pulmonology, and nephrology.SEC 8-K
- 2025-06-30partnershipMyrtle Recovery Centers approved to receive Scott County Opioid Abatement Funds for a second year starting July 1, 2025.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.